Efficacy and Mechanism of Angiotensin II Receptor Blocker Treatment in Experimental Abdominal Aortic Aneurysms

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Iida, Yasunori ^a   Xu, Baohui ^a   Schultz, Geoffrey M ^a   Chow, Vinca ^a   White, Julie J ^a   Sulaimon, Shola ^b   Hezi Yamit, Ayala ^b   Peterson, Susan Rea ^b   Dalman, Ronald L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; DOXYCYCLINE; FLUINDOSTATIN; IRBESARTAN; TELMISARTAN;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ELASTOLYSIS; EXPERIMENTAL MODEL; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MIGRATION INHIBITION; MORTALITY; MOUSE; NONHUMAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; DOXYCYCLINE; FATTY ACIDS, MONOUNSATURATED; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SULFONAMIDES; TETRAZOLES;

MUS; SUS;

EID: 84870700463     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049642     Document Type: Article

References (96)

1. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM, (2009) Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular 17: 253-263.
2. Trollope A, Moxon JV, Moran CS, Golledge J, (2011) Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 20: 114-123.
3. Baxter BT, Terrin MC, Dalman RL, (2008) Medical management of small abdominal aortic aneurysms. Circulation 117: 1883-1889.
4. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, et al. (2009) The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 50: S2-49.
5. Blanchard JF, Armenian HK, Friesen PP, (2000) Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol 151: 575-583.
6. Lu H, Rateri DL, Cassis LA, Daugherty A, (2008) The role of the renin-angiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep 10: 99-106.
7. Kaschina E, Scholz H, Steckelings UM, Sommerfeld M, Kemnitz UR, et al. (2009) Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis 205: 396-403.
8. Daugherty A, Cassis L, (1999) Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 892: 108-118.
9. Daugherty A, Manning MW, Cassis LA, (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612.
10. Rateri DL, Moorleghen JJ, Balakrishnan A, Owens AP, 3rd, Howatt DA,et al. Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res 108: 574-581.
11. Cassis LA, Rateri DL, Lu H, Daugherty A, (2007) Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 27: 380-386.
12. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, et al. (2001) Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 33: 1057-1064.
13. Daugherty A, Manning MW, Cassis LA, (2001) Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134: 865-870.
14. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, et al. (2008) Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 22: 703-708.
15. Kaschina E, Schrader F, Sommerfeld M, Kemnitz UR, Grzesiak A, et al. (2008) Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 26: 2361-2373.
16. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, et al. (2010) An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 52: 55-61.
17. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT, (2010) Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 52: 1-4.
18. Hackam DG, Thiruchelvam D, Redelmeier DA, (2006) Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 368: 659-665.
19. Burnier M, (2009) Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 37: 1662-1679.
20. Vinh A, Gaspari TA, Liu HB, Dousha LF, Widdop RE, et al. (2008) A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res 45: 143-152.
21. Sho E, Chu J, Sho M, Fernandes B, Judd D, et al. (2004) Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 39: 1312-1321.
22. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, et al. (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105: 1641-1649.
23. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, et al. (1996) Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23: 336-346.
24. Manning MW, Cassis LA, Daugherty A, (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 23: 483-488.
25. Dodd BR, Spence RA (2011) Doxycycline Inhibition of Abdominal Aortic Aneurysm Growth- A Systematic Review of the Literature. Curr Vasc Pharmacol.
26. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R, (2009) Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119: 2209-2216.
27. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, et al. (2005) Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 241: 92-101.
28. Wang JA, Chen WA, Wang Y, Zhang S, Bi H, et al. (2011) Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms. Atherosclerosis 217: 90-96.
29. Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, et al. (2009) Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 29: 1764-1771.
30. Golledge J, Cullen B, Moran C, Rush C (2010) Efficacy of Simvastatin in Reducing Aortic Dilatation in Mouse Models of Abdominal Aortic Aneurysm. Cardiovasc Drugs Ther.
31. Hamblin M, Chang L, Zhang H, Yang K, Zhang J, et al. (2010) Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma deletion promotes abdominal aortic aneurysms. J Vasc Surg 52: 984-993.
32. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117-121.
33. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, et al. (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112: 1318-1331.
34. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, et al. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110: 625-632.
35. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A, 3rd, et al (2009) An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 119: 3637-3651.
36. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, et al. (2010) TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 120: 422-432.
37. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, et al. (2004) Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 24: e174-178.
38. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, et al. (2004) The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10: 966-973.
39. Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, et al. (2009) Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 183: 2741-2746.
40. Ahluwalia N, Lin AY, Tager AM, Pruitt IE, Anderson TJ, et al. (2007) Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 179: 691-697.
41. Frutkin AD, Otsuka G, Stempien-Otero A, Sesti C, Du L, et al. (2009) TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 29: 1251-1257.
42. Nakahashi TK, Hoshina K, Tsao PS, Sho E, Sho M, et al. (2002) Flow loading induces macrophage antioxidative gene expression in experimental aneurysms. Arterioscler Thromb Vasc Biol 22: 2017-2022.
43. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
44. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, et al. (2001) Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 37: 587-593.
45. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, et al. (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541.
46. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, et al. (2009) Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 106: 14942-14947.
47. Satta J, Soini Y, Mosorin M, Juvonen T, (1998) Angiogenesis is associated with mononuclear inflammatory cells in abdominal aortic aneurysms. Ann Chir Gynaecol 87: 40-42.
48. Choke E, Cockerill GW, Dawson J, Wilson RW, Jones A, et al. (2006) Increased angiogenesis at the site of abdominal aortic aneurysm rupture. Ann N Y Acad Sci 1085: 315-319.
49. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, et al. (2009) Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 29: 1452-1457.
50. Paik DC, Fu C, Bhattacharya J, Tilson MD, (2004) Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 36: 524-533.
51. Nackman GB, Karkowski FJ, Halpern VJ, Gaetz HP, Tilson MD, (1997) Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. Surgery 122: 39-44.
52. Miskinyte S, Butler MG, Herve D, Sarret C, Nicolino M, et al. (2011) Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet 88: 718-728.
53. Kaneko H, Anzai T, Takahashi T, Kohno T, Shimoda M, et al. (2011) Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 91: 358-367.
54. Miwa K, Nakashima H, Aoki M, Miyake T, Kawasaki T, et al. (2005) Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Ther 12: 1109-1118.
55. Choke E, Cockerill GW, Dawson J, Howe F, Wilson WR, et al. (2010) Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice. J Vasc Surg 52: 159-166.
56. Sho E, Sho M, Nanjo H, Kawamura K, Masuda H, et al. (2004) Hemodynamic regulation of CD34+ cell localization and differentiation in experimental aneurysms. Arterioscler Thromb Vasc Biol 24: 1916-1921.
57. Nishibe T, Dardik A, Kondo Y, Kudo F, Muto A, et al. (2010) Expression and localization of vascular endothelial growth factor in normal abdominal aorta and abdominal aortic aneurysm. Int Angiol 29: 260-265.
58. Kobayashi M, Matsubara J, Matsushita M, Nishikimi N, Sakurai T, et al. (2002) Expression of angiogenesis and angiogenic factors in human aortic vascular disease. J Surg Res 106: 239-245.
59. Carbajo-Lozoya J, Lutz S, Feng Y, Kroll J, Hammes HP, et al. (2012) Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal 25: 1261-1269.
60. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, et al. (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112: 67-75.
61. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, et al. (2002) Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 109: 603-611.
62. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA, et al. (2010) Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 118: 681-689.
63. Moehle CW, Bhamidipati CM, Alexander MR, Mehta GS, Irvine JN, et al. (2011) Bone marrow-derived MCP1 required for experimental aortic aneurysm formation and smooth muscle phenotypic modulation. J Thorac Cardiovasc Surg 142: 1567-1574.
64. Koch AE, Kunkel SL, Pearce WH, Shah MR, Parikh D, et al. (1993) Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am J Pathol 142: 1423-1431.
65. Colonnello JS, Hance KA, Shames ML, Wyble CW, Ziporin SJ, et al. (2003) Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm. J Vasc Surg 38: 138-146.
66. Abisi S, Burnand KG, Waltham M, Humphries J, Taylor PR, et al. (2007) Cysteine protease activity in the wall of abdominal aortic aneurysms. J Vasc Surg 46: 1260-1266.
67. Gordon S, Martinez FO, (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
68. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, et al. (2011) Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 31: 2856-2864.
69. Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y, et al. (2010) Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension 55: 1267-1274.
70. Huffman MD, Curci JA, Moore G, Kerns DB, Starcher BC, et al. (2000) Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 128: 429-438.
71. Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA (2004) Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 78: 2106-2110; discussion 2110-2101.
72. Onoda M, Yoshimura K, Aoki H, Ikeda Y, Morikage N, et al. (2010) Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm. Atherosclerosis 208: 366-369.
73. Maki JM, Rasanen J, Tikkanen H, Sormunen R, Makikallio K, et al. (2002) Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 106: 2503-2509.
74. Wiernicki I, Stachowska E, Safranow K, Cnotliwy M, Rybicka M, et al. (2010) Enhanced matrix-degrading proteolytic activity within the thin thrombus-covered wall of human abdominal aortic aneurysms. Atherosclerosis 212: 161-165.
75. Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, et al. (2007) Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 8: 237.
76. McCormick ML, Gavrila D, Weintraub NL, (2007) Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 27: 461-469.
77. Hordijk PL, (2006) Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 98: 453-462.
78. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, et al. (2011) Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332: 361-365.
79. Tsubakimoto Y, Yamada H, Yokoi H, Kishida S, Takata H, et al. (2009) Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol 29: 1529-1536.
80. Suen RS, Rampersad SN, Stewart DJ, Courtman DW, (2011) Differential Roles of Endothelin-1 in Angiotensin II-Induced Atherosclerosis and Aortic Aneurysms in Apolipoprotein E-Null Mice. Am J Pathol 179: 1549-1559.
81. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, et al. (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45: 154-162.
82. Jones A, Deb R, Torsney E, Howe F, Dunkley M, et al. (2009) Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 119: 3125-3132.
83. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, et al. (2010) Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 210: 51-56.
84. Stalenhoef AF, (2009) The benefit of statins in non-cardiac vascular surgery patients. J Vasc Surg 49: 260-265.
85. Takagi H, Matsui M, Umemoto T, (2010) A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 52: 1675-1681.
86. Twine CP, Williams IM Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 98: 346-353.
87. Van Kuijk JP, Flu WJ, Witteveen OP, Voute M, Bax JJ, et al. (2009) The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 50: 599-609.
88. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S, (2006) Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97: 279-280.
89. Shiraya S, Miyake T, Aoki M, Yoshikazu F, Ohgi S, et al. (2009) Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 202: 34-40.
90. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, et al. (2006) Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32: 21-26.
91. Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, et al. (2006) Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 43: 117-124.
92. Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, et al. (2008) In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ Cardiovasc Imaging 1: 220-226.
93. Goergen CJ, Barr KN, Huynh DT, Eastham-Anderson JR, Choi G, et al. (2010) In vivo quantification of murine aortic cyclic strain, motion, and curvature: implications for abdominal aortic aneurysm growth. J Magn Reson Imaging 32: 847-858.
94. Nagy N, Melchior-Becker A, Fischer JW, (2010) Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis. Basic Res Cardiol 105: 29-38.
95. Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, et al. (2004) Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110: 3062-3067.
96. Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, et al. (2007) The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 67: 10428-10435.